The efficacy, safety, and the predictive factors of efficacy of Bird therapy

The efficacy, safety, and the predictive factors of efficacy of Bird therapy - Bird trail

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013959

Enrollment

Registered

2014-05-14

Start date

2013-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

treatment of Lenalidomide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: According to the International Myeloma Working Group (IMWG) criteria, patients younger than 75 years with symptomatic MM were eligible for this trial.

Exclusion criteria

Exclusion criteria: The exclusion criteria were a serum creatinine level>2.05 mg/dL, liver dysfunction (e.g., a serum total bilirubin level>2.0 mg/dL, or serum aspartate/alanine aminotransferase or alkaline phosphatase levels more than 2.5 times the upper limit of normal), grade 3 or worse peripheral neuropathy, significant comorbidity that would preclude ASCT, poor performance status (>grade 3), and a history of any other malignancy with the exception of basal cell carcinoma and stage I cervical cancer.

Design outcomes

Primary

Measure	Time frame
complete response rate	—

Secondary

Measure	Time frame
1)CTL Ratio in the peripheral blood 2)Blood concentration of lenalidomide 3)Cytokine concentration 4)Chemokine concentration 5)Safety	—

Countries

Japan

Contacts

Public ContactNaoki Takezako

National Hospital Organization Disaster Medical Center of Japan Department of Hematology

ntakezak@gmail.com042-526-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026